Yet a U.S. randomized controlled trial on the effectiveness of prostate cancer screening showed no prostate-cancer-specific mortality reduction at all [1], which has led the U.S. Preventive Services Task Force and other medical organizations to recommend against PSA screening. The gene discussed is KLK3; the disease is prostate carcinoma.